Humedica, a Boston-based clinical informatics company, has raised $20 million in a round of equity financing, according to an SEC filing. The firm, which previously raised $30 million from Bain Capital Ventures, General Catalyst Partners, North Bridge Venture Partners, and the investment bank Leerink Swann in summer 2008, came out of stealth mode in September 2009. According to its SEC filing for this latest round, all of the company’s previous backers are represented on its board of directors. Paul Bleicher, who is listed as a director of the company, was founding CEO and chairman of Phase Forward, the Waltham, MA-based provider of clinical trials software that tech giant Oracle (NASDAQ:ORCL) bought last year in a deal valued at $685 million.
By posting a comment, you agree to our terms and conditions.